GLP1R and Parkinson disease: This suggests that GLP-1 agonists suppress the pro-apoptotic activation of JNK in dopaminergic neurons by enhancing anti-oxidative mechanisms (as elucidated below), preventing ROS-generation due to mitochondrial dysfunction and quenching microglial and astroglia inflammation during PD (more insight in section “Inflammation”).